Veracyte

VCYT

Market cap $2.62B

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be av.

VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.

VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.

The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to performance for both the quarter and year. Management highlighted strong demand for high-speed optical components supporting AI-driven data center growth, alongside improving margins.

Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript

Veracyte (VCYT) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. “We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter,” said Marc Stapley, Veracyte's chief executive officer. “We are achieving this growth while mai.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCOGU--Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium.